Americans seek compensation for failed COVID-19 treatments from U.S.
fund
Send a link to a friend
[March 11, 2021] By
Tom Hals
In March of last year, Steve Cicala took
his wife, Susan, to the emergency room at Clara Maass Medical Center in
New Jersey to treat a worsening cough and fever, unaware she had
COVID-19.
As her breathing and blood pressure deteriorated, she was given
azithromycin and hydroxychloroquine and put on a ventilator. Eleven days
after being admitted to the same hospital where she had worked for years
as a nurse, Susan went into cardiac arrest and died at age 60.
Steve Cicala is now the first person known to be pursuing a COVID-19
claim with a decade-old U.S. government fund that has up to $30 billion
that can be used to compensate for serious injuries or deaths caused by
treatments or vaccines in the fight against the pandemic.
COVID-19 presents the first serious test of the Countermeasure Injury
Compensation Program (CICP) overseen by the Department of Health and
Human Services (HHS). The program so far has denied compensation in 90%
of the cases filed prior to the pandemic, mostly for H1N1 flu vaccines.
Cicala's claim has not been previously reported.
He could receive around $367,000 from the virtually untapped fund if he
can show the treatment caused his wife's death. He is not alleging
negligence against the hospital, which is largely protected from
liability by an emergency health law.
"There's nothing that's going to bring her back," said Cicala, "but
obviously with our two children and now two grandchildren, if there's
something that we could do to help them out, that would be nice."
Cicala, 58, said he believed the hospital provided the best care
possible. Clara Maass declined to comment.
A DEADLY COMBINATION
The government does not publish specifics of claims to the fund, the
amount of payouts or why claims are denied. HHS declined to comment.
A Freedom of Information Act disclosure brought by a law professor and
viewed by Reuters shows 48 claims were filed this year and were pending
as of Feb. 16, for serious injuries and deaths from vaccines,
ventilators and drugs - figures that have not previously been reported.
All of these claims were related to COVID-19.
To encourage life-saving efforts during a declared public health
emergency, healthcare providers and drug companies can be shielded from
nearly all lawsuits, and claims for serious injuries or deaths are
instead filed with the CICP.
That legal protection extends to COVID-19 vaccines by Moderna Inc,
Pfizer Inc and partner BioNTech SE, and Johnson & Johnson, as well as
approved medicines, which briefly included the antimalaria drug
hydroxychloroquine touted by former President Donald Trump.
U.S. regulators revoked the emergency authorization for
hydroxychloroquine after studies suggested it was not effective and may
pose heart risks for certain patients.
Electrocardiogram records show Susan Cicala's heart rhythms were
disrupted by hydroxychloroquine and azithromycin, according to her
husband's lawyer, Jonathan Levitt of Frier Levitt.
[to top of second column] |
The drug hydroxychloroquine, pushed by U.S. President Donald Trump
and others in recent months as a possible treatment to people
infected with the coronavirus disease (COVID-19), is displayed by a
pharmacist at the Rock Canyon Pharmacy in Provo, Utah, U.S., May 27,
2020. REUTERS/George Frey/
"Those two in combination are known to be deadly now," said Levitt. "And she was
also placed on a ventilator, which as you know, also has some substantial
dangers."
Cicala's is one of about a dozen claims Levitt has filed with the fund. He said
he has more than 200 clients planning to seek compensation for deaths allegedly
caused by failed COVID-19 treatments.
"Our cases are mostly about hydroxychloroquine," said Levitt, who gets paid a
portion of successful claims, though he declined to say how much.
U.S. lawsuits over some drugs have run into billions of dollars and protection
against liability was seen as key to developing vaccines at breakneck speed
during a pandemic.
However, critics said the compensation fund pays out relatively small amounts
for serious injuries and lacks transparency.
In its 10-year history, the fund has paid $6 million for 29 claims for vaccine
injuries, according to disclosures obtained by Peter Meyers, a Georgetown Law
professor and vaccine injury specialist, and viewed by Reuters. Most of those
were for the neurological disorder Guillain-Barré syndrome caused by the H1N1
flu vaccine.
The U.S. Centers for Disease Control and Prevention (CDC) estimates about 123
million people received the H1N1 vaccine.
Of the 48 coronavirus-related claims received by the fund, 21 involved COVID-19
vaccines, including three deaths, according to the FOIA information obtained by
Meyers.
The CDC said it has received reports of deaths among people who received
COVID-19 vaccines, but has no evidence linking the shots to the fatalities.
Based on Meyers' FOIA information, it appears fewer than 25 claims were filed in
2020, and it was not clear whether these were COVID-19 related.
Through the end of January, more than 25 million people in the United States
received at least one coronavirus vaccine dose. Meyers said the number of
vaccine claims suggests the shots are extremely safe.
Still, he said the program's lack of transparency could undermine support for
protecting drug companies from lawsuits and for drugs and vaccines authorized
for emergency use.
"It’s important to have openness to gain the trust of the American public and to
counter the vaccine hesitancy,” he said.
(Reporting by Tom Hals in Wilmington, Delaware; Editing by Noeleen Walder and
Bill Berkrot)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |